Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 15/20 | 1.00 |
| ▸ | MMP3 | P08254 | 11/20 | 1.00 |
| ▸ | MMP13 | P45452 | 11/20 | 1.00 |
| ▸ | MMP9 | P14780 | 11/20 | 1.00 |
| ▸ | MMP1 | P03956 | 10/20 | 1.00 |
| ▸ | MMP7 | P09237 | 9/20 | 1.00 |
| ▸ | MMP14 | P50281 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7409456 | 1.00 | MMP2 (1.00) | MMP2MMP3MMP13MMP9MMP1 | |
| SCHEMBL15251876 | 0.96 | MMP2 (0.92) | MMP2MMP3MMP13MMP9MMP1 | |
| SCHEMBL7062881 | 0.96 | MMP2 (0.92) | MMP2MMP3MMP13MMP9MMP1 | |
| SCHEMBL21067512 | 0.90 | MMP2 (0.82) | MMP2MMP3MMP13MMP9MMP1 | |
| SCHEMBL31086926 | 0.90 | MMP2 (0.82) | MMP2MMP3MMP13MMP9MMP1 | |
| SCHEMBL21067511 | 0.90 | MMP2 (0.82) | MMP2MMP3MMP13MMP9MMP1 | |
| SCHEMBL3969625 | 0.83 | MMP9 (0.71) | MMP2MMP3MMP13MMP9MMP1 | |
| SCHEMBL7066619 | 0.83 | MMP9 (0.71) | MMP2MMP3MMP13MMP9MMP1 | |
| SCHEMBL11351046 | 0.83 | MMP9 (0.71) | MMP2MMP3MMP13MMP9MMP1 | |
| SCHEMBL15251807 | 0.83 | MMP2 (0.70) | MMP2MMP3MMP13MMP9MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0901466-B1 | BIPHENYLSULFONAMIDE MATRIX METALLOPROTEINASE INHIBITORS | WARNER LAMBERT CO (US) | 2001-10-31 | — | — | EP | claimed |
| CN-1310629-A | Combined administration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions | WARNER LAMBERT CO (US) | 2001-08-29 | — | — | CN | claimed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | claimed |
| EP-0901466-A1 | BIPHENYLSULFONAMIDE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1999-03-17 | — | — | EP | claimed |
| US-5756545-A | ANTIARTHRITIC AGENTS; OSTEOPOROSIS | WARNER-LAMBERT COMPANY (US) | 1998-05-26 | — | — | US | claimed |
| WO-1997044315-A1 | BIPHENYLSULFONAMIDE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1997-11-27 | — | — | WO | claimed |
| EP-0901466-B1 | BIPHENYLSULFONAMIDE MATRIX METALLOPROTEINASE INHIBITORS | WARNER LAMBERT CO (US) | 2001-10-31 | — | — | EP | disclosed |
| US-5756545-A | ANTIARTHRITIC AGENTS; OSTEOPOROSIS | WARNER-LAMBERT COMPANY (US) | 1998-05-26 | — | — | US | disclosed |